Graft Versus Host Disease (GVHD)

Letter on the Bipartisan Senate FY25 Labor-HHS-Education Appropriations Bill

Original Publication Date
Article Source
Coalition Action
AAMDSIF is Taking a Stand for NIH Research Research programs led by the National Institutes of Health (NIH) forge the way for life-saving new treatments for rare diseases such as aplastic anemia, MDS, and PNH. With clinical research locations throughout the U.S., researchers and…

FDA Approves Axatilimab in 9 Mg and 22 Mg Vial Sizes for GVHD

Original Publication Date
Article Source
External Web Content
Axatilimab-csfr (Niktimvo), a CSF-1R–targeting agent that reduces the drivers of inflammation and fibrosis, has been approved by the FDA in 9 mg and 22 mg vial sizes to treat adult and pediatric patients with graft-versus-host disease (GVHD), according to a news release from the…

Can JAK inhibition prevent GVHD?

Original Publication Date
Article Source
External Web Content
In this issue of Blood, Pidala et al report on the results of a multicenter phase 2 trial, in which a graft-versus-host disease (GVHD) prevention regimen of pacritinib, an oral JAK2 inhibitor, in combination with sirolimus and tacrolimus successfully suppressed pSTAT3 signaling…

Fatigue Management

Thumbnail for video Watch Now

Topic(s)
Living Well with Bone Marrow Failure
Presenter(s)
Timothy Pearman, PhD
Jenny Finkel
In this webinar, Dr. Tim Pearman discusses fatigue and how it can be best managed. Jenny Finkle demonstrates some gentle exercises you can do to increase your energy level. This was an interactive session.
Subscribe to Graft Versus Host Disease (GVHD)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.